In 1973, Billups-Rothenberg Inc. (BRI) pioneered the development of low-cost tissue culture incubators. Nearly 50 years later, these proven designs have become the de facto standard for hypoxic experiments. The products provide a full range of O2/CO2 conditions for tissue culture incubators and enable various in vitro environments. These tools are mainstays in fields such as stem cell, IVF, and malaria research in thousands of laboratories worldwide.
In 2021, BRI was sold to a newly created company, Embrient Inc., to continue selling BRI products and to provide funding for future, innovative new products. The entire BRI product line and management team were retained intact.